For SARS-CoV-2 vaccine spike proteins should be processed to induce both T-cell and antibody-mediated immunity to COVID-19, since coating the adenovirus with peptides specifically selected for CD8+ T-cells increase the cell-mediated immune response broadening the immune targets. This evidence concerns the gene CD8A and COVID-19.